{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:26Z","timestamp":1790730746551,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"IRCCS Istituto Giannina Gaslini of Genoa","award":["FIS 2021 grant 2235"],"award-info":[{"award-number":["FIS 2021 grant 2235"]}]},{"DOI":"10.13039\/501100004702","name":"University of Genoa","doi-asserted-by":"publisher","award":["RC24\/2017"],"award-info":[{"award-number":["RC24\/2017"]}],"id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004702","name":"University of Genoa","doi-asserted-by":"publisher","award":["RC30\/2022"],"award-info":[{"award-number":["RC30\/2022"]}],"id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IRCCS Burlo Garofolo of Trieste"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Type I Interferon (IFN) induced gene expression analysis (\u201cIFN signature\u201d) is employed to categorize pathological conditions that exhibit Type I IFN dysregulation and to direct customized therapeutic strategies. For instance, it is used to differentiate patients with IFN-related inflammation from those with conditions primarily mediated by other cytokines, such as juvenile idiopathic arthritis and periodic fevers. Nevertheless, there is currently no standardized method available for clinical practice, and comparing values at different time points or between centers poses a challenge. In this work, we described a standardized method based on the development and validation of a synthetic control to solve the problem of test comparison.<\/jats:p>\n               <jats:p>Inter-assay and inter-laboratory variability were assessed by multiple repeated analyses within the same laboratory, and between two different laboratories involved in the study. The method has been validated by evaluating the IFN signature of 39 patients with inflammatory disorders known to be related or not to Type I IFN (i.e. monogenic interferonopathies, systemic lupus erythematosus, juvenile dermatomyositis, periodic fevers, and juvenile idiopathic arthritis).<\/jats:p>\n               <jats:p>The proposed method proved to be highly reproducible among centers and able to discriminate among IFN-related or non-IFN-related inflammation.<\/jats:p>\n               <jats:p>The use of a synthetic control minimized the inter-assay and inter-laboratory variability, and thus facilitate data sharing among centers to improve knowledge of IFN-related inflammation and patient\u2019s care.<\/jats:p>","DOI":"10.1093\/cei\/uxaf018","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:47:56Z","timestamp":1743223676000},"source":"Crossref","is-referenced-by-count":10,"title":["Type I interferon signature: a quantitative standardized method for clinical application"],"prefix":"10.1093","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-3794","authenticated-orcid":false,"given":"Alessandra","family":"Tesser","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo , Trieste,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bocca","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ulivi","sequence":"additional","affiliation":[{"name":"TIB Molbiol Syntheselabor GmbH , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo , Trieste,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cangelosi","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Santori","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Drago","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]},{"name":"Dipartimento Di Neuroscienze, Riabilitazione, Oftalmologia Genetica e Scienze Materno-Infantili (DINOGMI), University of Genoa , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-7846","authenticated-orcid":false,"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-6042","authenticated-orcid":false,"given":"Fabio","family":"Candotti","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne , Lausanne,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1916","authenticated-orcid":false,"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo , Trieste,","place":["Italy"]},{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste , Trieste,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7129-868X","authenticated-orcid":false,"given":"Stefano","family":"Volpi","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini , Genoa,","place":["Italy"]},{"name":"Dipartimento Di Neuroscienze, Riabilitazione, Oftalmologia Genetica e Scienze Materno-Infantili (DINOGMI), University of Genoa , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2025042508563594800_CIT0001","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"2025042508563594800_CIT0002","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"2025042508563594800_CIT0003","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"key":"2025042508563594800_CIT0004","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025042508563594800_CIT0005","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jmg.40.3.183","article-title":"Cree encephalitis is allelic with Aicardi","volume":"40","author":"Crow","year":"2003","journal-title":"J Med Genet"},{"key":"2025042508563594800_CIT0006","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025042508563594800_CIT0007","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"2025042508563594800_CIT0008","doi-asserted-by":"publisher","first-page":"Article ID 374312","DOI":"10.4061\/2009\/374312","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti-IFN-\u03b1 monoclonal antibody trials in systemic lupus erythematosus","volume":"1","author":"Yao","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"2025042508563594800_CIT0009","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025042508563594800_CIT0010","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"2025042508563594800_CIT0011","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"2025042508563594800_CIT0012","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025042508563594800_CIT0013","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using nanostring technology","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"2025042508563594800_CIT0014","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"key":"2025042508563594800_CIT0015","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1093\/rheumatology\/keac083","article-title":"Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study","volume":"61","author":"Wahadat","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025042508563594800_CIT0016","doi-asserted-by":"publisher","first-page":"e003211","DOI":"10.1136\/rmdopen-2023-003211","article-title":"Assessment of type I interferon response in routine practice in France in 2022","volume":"9","author":"Nombel","year":"2023","journal-title":"RMD Open"},{"key":"2025042508563594800_CIT0017","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/acr2.11618","article-title":"Type 1 interferon-stimulated gene expression and disease activity in pediatric rheumatic diseases: no composite scores needed","volume":"5","author":"Weiden","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025042508563594800_CIT0018","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/diagnostics9030113","article-title":"An easy and reliable strategy for making type I interferon signature analysis comparable among research centers","volume":"9","author":"Pin","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"2025042508563594800_CIT0019","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025042508563594800_CIT0020","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025042508563594800_CIT0021","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025042508563594800_CIT0022","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025042508563594800_CIT0023","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J Clin Invest"},{"key":"2025042508563594800_CIT0024","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxaf018\/62574229\/uxaf018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf018\/62574229\/uxaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/219\/1\/uxaf018\/62574229\/uxaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:56:42Z","timestamp":1745585802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxaf018\/8092481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxaf018","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"uxaf018"}}